5th RAS-Targeted Drug Development Summit
The 5th RAS-Targeted Drug Development Summit returns to Boston this September.
With the recent approval of the second-ever KRAS G12C inhibitor, the industry looks to learn how to better target non-G12C mutations, validate novel targets in the RAS pathway, and experience the next generation of RAS-targeted drugs.
Set to unite 150+ key leaders in biopharma and academia in Boston, this year’s event has a strong focus in tackling emerging resistance mechanisms, assessing promising combination approaches, and exploring novel RAS therapies.
Hear from 45+ expert speakers across three jam-packed days and two dedicated tracks of content, with the likes of Mirati Therapeutics, Revolution Medicines, Amgen, Novartis, Roche, Loxo Oncology@Lilly, BridgeBio, Pfizer, and Genentech all sharing their latest data-led clinical updates.
Don’t miss out on the only industry-dedicated, end-to-end forum focused on accelerating best-in-class RAS therapies throughout the entire clinical pipeline
